Latest Announcements

Investor Announcement

PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders

Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration

 

Investor Announcement

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

Prana Biotechnology is pleased to announce the first cohort of volunteers in its Phase I clinical trial have been administered PBT434, an experimental drug under investigation for the treatment of Parkinsonian diseases.

Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"